Evidence map›Paper›PMID 35596155›Full record

ArticleBMC cancer2022

Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.

Yaoxiang Tang, Jiadi Luo, Ying Zhou, Hongjing Zang, Yang Yang, Sile Liu, Hongmei Zheng, Jian Ma, Songqing Fan, Qiuyuan Wen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  2. Article
  3. Review
  4. Advances in lymphatic metastasis of non-small cell lung cancer.Cell communication and signaling : CCS · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yaoxiang TangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Jiadi LuoDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Ying ZhouDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Hongjing ZangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yang YangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Sile LiuDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Hongmei ZhengDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Jian MaCancer Research Institute of Central South University, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, 410011, Hunan, China.
Songqing FanDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Qiuyuan WenDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. wenqiuyuan@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRibosomal protein S6 (S6), a downstream effect media of the AKT/mTOR pathway, not only is a part of 40S small subunit of eukaryotic ribosome, but also involves in protein synthesis and cell proliferation during cancer development.

methodsIn present study, we explore the association between phosphorylated S6 (p-S6) protein expression and clinicopathological features as well as prognostic implications in NSCLC. P-S6 was detected in tissue microarrays (TMAs) containing 350 NSCLC, 53 non-cancerous lung tissues (Non-CLT), and 88 cases of matched metastatic lymph node lesions via immunohistochemistry (IHC). Transwell assays and wound healing assay were used to assess the effects of p-S6 inhibition on NSCLC cell metastasis.

resultsThe p-S6 expression in NSCLC was more evident than that in Non-CLT (p < 0.05). Compared to NSCLC patients who have no lymph node metastasis (LNM), those with LNM had higher p-S6 expression (p = 0.001). Regardless of lung squamous cell carcinoma (SCC) or adenocarcinoma (ADC), p-S6 was increased obviously in metastatic lymph nodes compared with matched primary cancers (p = 0.001, p = 0.022, respectively). Inhibition of p-S6 decreased the metastasis ability of NSCLC cells. In addition, p-S6 was an independent predicted marker for LNM in patients with NSCLC (p < 0.001). According to survival analysis, patients with highly expressed p-S6 had a lower survival rate compared with that with lower expression (p = 0.013). P-S6 is an unfavorable independent prognostic factor for NSCLC patients (p = 0.011).

conclusionIncreased expression of p-S6 is not only a novel predictive biomarker of LNM but also poor prognosis in NSCLC.

Indexed as

AdenocarcinomaCarcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansLymphatic MetastasisNeoplasm StagingPrognosisBiomarkers, TumorLymph node metastasisNon-small cell lung cancerPrognosisP-S6

Identifiers

PMID35596155
PMCPMC9123697
OpenAlexW4280644005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.